Vonoprazan versus lansoprazole in the treatment of artificial gastric ulcers after endoscopic submucossal dissection: a randomized, open-label trial.

Abstract

BACKGROUND:

Vonoprazan is more potent and longer acting than traditional proton pump inhibitor. Although vonoprazan is expected to be superior to proton pump inhibitor, its efficacy in the treatment of gastric ulcers following endoscopic submucosal dissection (ESD) is not fully understood. The aim of this study was to evaluate the effectiveness of vonoprazan in artificial ulcer healing following ESD.

METHODS:

Patients with gastric tumors were randomly assigned to the vonoprazan group (group V) or lansoprazole group (group L) after ESD. Patients received intravenous lansoprazole (30 mg) twice on the day of ESD. Thereafter, patients were treated with vonoprazan (20 mg/day) in group V or lansoprazole (30 mg/day) in group L. Esophagogastroduodenoscopy was performed 4 and 8 weeks after the ESD.

RESULTS:

A total of 168 patients were analyzed. The 4-week healing rate for artificial ulcer was not significantly higher in group V versus group L (17/85, 20.0% vs. 14/83, 16.9%, respectively). In addition, there were no significant differences between the 4-week shrinkage rates between the two groups. Postoperative bleeding occurred in none of the patients in group V and three in group L. One patient in group V presented delayed perforation 2 days after ESD.

CONCLUSIONS:

Vonoprazan might not be superior to lansoprazole in the healing of artificial gastric ulcer after ESD.

TRIAL REGISTRATION:

University hospital Medical Information Network (registration number: UMIN000016642), Registered 27 February 2015, https://www.umin.ac.jp/ctr/index-j.htm.

• Authors: Daisuke Kawai, Ryuta Takenaka, Mikako Ishiguro, Shotaro Okanoue, Tatsuhiro Gotoda, Yoshiyasu Kono, Koji Takemoto, Hirofumi Tsugeno, Shigeatsu Fujiki
• Journal: BMC gastroenterology (BMC Gastroenterol) Vol. 21 Issue 1 Pg. 236 (May 22 2021) ISSN: 1471-230X [Electronic] England
• PMID: 34022796 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine
• Proton Pump Inhibitors
• Pyrroles
• Sulfonamides
• Lansoprazole

Topics

• Dissection
• Endoscopic Mucosal Resection
• Humans
• Lansoprazole (therapeutic use)
• Prospective Studies
• Proton Pump Inhibitors (adverse effects)
• Pyrroles
• Stomach Neoplasms
• Stomach Ulcer (drug therapy, etiology)
• Sulfonamides